In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Molecules and Big Pharma

Executive Summary

"Catch a wave and you're sitting on top of the world." Richard DiMarchi, Eli Lilly & Co.'s group VP, research technologies, recalled Brian Wilson's lyric at Windhover Information Inc.'s 2001 Pharmaceutical Strategic Alliances conference as he pointed to a chart illustrating the exponential growth of genetic information generated over the past five years. "The question here," remarked DiMarchi, "is whether you can surf a Tsunami." Citing recent reports from Accenture and Lehman Brothers warning the drug industry to exercise extreme care in attempting to commercially exploit the fruits of genomics, DiMarchi went on to advise, "I think you're going to need a heckuva lot of wax to surf this wave, but this is where the future is and you need to be a part of it." One way for drug companies to compete in this new environment is to have the flexibility to work in both large molecule and small molecule therapeutics. Lilly has a strong commitment to protein-based drugs, and, in his presentation, DiMarchi discussed the economic/scientific advantages of working in small molecules, as well as the obstacles for companies that choose to do so.
Advertisement

Related Content

In Sepsis, Having the Right Drug Still May Not Be Enough
Protein C: Saving Lives, Saving Lilly

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel